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Impact of Diabetes Mellitus on the Evaluation of Stable Chest Pain
Patients: Insights From the PROMISE (Prospective Multicenter
Imaging Study for Evaluation of Chest Pain) Trial
Abhinav Sharma, MD; Nishant K. Sekaran, MD; Adrian Coles, PhD; Neha J. Pagidipati, MD, MPH; Udo Hoffmann, MD; Daniel B. Mark, MD,
MPH; Kerry L. Lee, PhD; Hussein R. Al-Khalidi, PhD; Michael T. Lu, MD; Patricia A. Pellikka, MD; Quynh A. Trong, MD, MPH;
Pamela S. Douglas, MD
Background-—The impact of diabetes mellitus on the clinical presentation and noninvasive test (NIT) results among stable
outpatients presenting with symptoms suggestive of coronary artery disease (CAD) has not been well described.
Methods and Results-—The PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) trial enrolled 10 003
patients with known diabetic status, of whom 8966 were tested as randomized and had interpretable NIT results (1908 with
diabetes mellitus, 21%). Differences in symptoms and NIT results were evaluated using logistic regression. Patients with diabetes
mellitus (versus without) were similar in age (median 61 versus 60 years) and sex (female 54% versus 52%), had a greater burden of
cardiovascular comorbidities, and had a similar likelihood of nonchest pain symptoms (29% versus 27%). The Diamond-Forrester/
Coronary Artery Surgery Study score predicted that patients with diabetes mellitus (versus without) had similar likelihood of
obstructive CAD (low 1.8% versus 2.7%; intermediate 92.3% versus 92.6%; high 5.9% versus 4.7%). Physicians estimated patients
with diabetes mellitus to have a higher likelihood of obstructive CAD (low to very low: 28.3% versus 40.1%; intermediate 63.9%
versus 55.9%; high to very high 7.8% versus 4.0%). Patients with diabetes mellitus (versus without) were more likely to have a
positive NIT result (15% versus 11%; adjusted odds ratio, 1.23; P=0.01).
Conclusions-—Stable chest pain patients with and without diabetes mellitus have similar presentation and pretest likelihood of
obstructive CAD; however, physicians perceive that patients with diabetes mellitus have a higher pretest likelihood of obstructive
CAD, an assessment supported by increased risk of a positive NIT. Further evaluation of diabetes mellitus’s inﬂuence on CAD
assessment is required.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov. Unique identiﬁer: NCT01174550. ( J Am Heart Assoc. 2017;6:
e007019. DOI: 10.1161/JAHA.117.007019.)
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I n the United States, over 29 million adults have adiagnosis of diabetes mellitus, and the prevalence will
grow in the next few decades.1 Although cardiovascular
disease is one of the leading causes of death and disability
among patients with diabetes mellitus,2,3 identifying these
patients remains a challenge—particularly among the major-
ity of patients who do not present with acute coronary
syndromes.4–7 Among stable symptomatic outpatients with
diabetes mellitus, there are few data regarding patient
demographic and presentation proﬁles, physician practice
with respect to noninvasive test (NIT) selection, rates of NIT
positivity, and predictors of NIT results, information which is
required to improve the value of healthcare services delivered
to this at-risk group. We analyzed these questions using
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contemporary data from the PROMISE (Prospective Multicen-
ter Imaging Study for Evaluation of Chest Pain), a randomized
trial of diagnostic evaluation strategy in 10 003 stable
outpatients with symptoms suggestive of coronary artery
disease (CAD).8,9 We compared symptomatic patients with
and without diabetes mellitus to assess: (1) demographic and
risk factor proﬁles; (2) clinical presentation; (3) physician
preference for functional stress test modality; (4) NIT results;
and (5) predictors of NIT positivity and the ability of these
predictors to discriminate for a positive NIT result.
Methods
Patient Population
The methods and results of the PROMISE trial have been
previously described.8,9 In brief, 10 003 symptomatic stable
outpatients without a history of CAD were randomized to
initial anatomical testing with 64-slice multi-detector coronary
computed tomographic angiography or functional testing
(exercise ECG, stress nuclear imaging, or stress echocardio-
gram). There were 2144 patients with diabetes mellitus (21%)
and 7858 without diabetes mellitus (79%); diabetic status of 1
patient was unknown. Before randomization, the local
providers were required to prespecify the functional test that
the patient would undergo should the patient be randomized
to that arm. Local or central institutional review boards
approved the study at the coordinating centers and each of
the 193 enrolling sites in North America. Patients provided
written informed consent before randomization.
Baseline Variable and Data Collection
Baseline patient data on demographics, risk factor proﬁles,
ECG ﬁndings, symptoms, and CAD risk estimates were
collected for all patients. Data from risk assessment scores
(2008 Framingham score,10 the 2013 Atherosclerotic Cardio-
vascular Disease [ASCVD] score,11 and the 2012 combined
Diamond-Forrester and CASS [Coronary Artery Surgery Study]
score12) were calculated for the entire population. In calculat-
ing the Framingham and ASCVD scores, the single imputation
method was used to replace missing values of cholesterol and
high-density lipoprotein with the mean of nonmissing observa-
tions, as described previously.13,14 In particular, the imputation
of cholesterol was stratiﬁed by history of dyslipidemia and
statin use at baseline, and the imputation of high-density
lipoprotein was stratiﬁed by sex. Test results according to site
interpretation were recorded for the ﬁrst NIT performed.
Overall, there were 8966 patients with an interpretable NIT
(1908 [21%] with diabetes mellitus and 7058 [79%] without
diabetes mellitus). On the coronary computed tomography
angiography scan, positivity was deﬁned as ≥70% major
epicardial stenosis or ≥50% left main stenosis. Positivity on
an exercise ECG was deﬁned as ST-segment changes consis-
tent with ischemia during stress being detected or if the test
was terminated early (<3 minutes) because of reproduction of
symptoms, arrhythmia, and/or hypotension. Positivity on
stress nuclear and stress echocardiography tests was deﬁned
as inducible ischemia in at least 1 coronary territory (septal/
anterior/apical; inferior/posterior; or lateral).
Statistical Analysis
Baseline characteristics were summarized using median
(25th, 75th percentiles) for continuous variables and frequen-
cies/percentages for categorical variables.
To determine whether the likelihood of a physician
preferring an imaging functional test over a nonimaging
functional test differed between diabetic and nondiabetic
patients, a multivariable generalized linear mixed model was
ﬁt using a generalized logit-link function. To determine
whether this relationship persisted after accounting for
demographic information, the model was adjusted for age,
sex, and testing site (as a random effect). A similar approach
was utilized to assess whether the likelihood of a physician
Clinical Perspective
What Is New?
• Using data from the PROMISE (Prospective Multicenter
Imaging Study for Evaluation of Chest Pain) trial, we
demonstrated that patients with and without diabetes
mellitus have similar clinical presentations.
• Patients with diabetes mellitus are more likely to be referred
for stress imaging tests than nonimaging tests and,
speciﬁcally, nuclear tests.
• Patients with and without diabetes mellitus have a similar
pretest likelihood of obstructive coronary artery disease
based on the Diamond-Forrester and Coronary Artery
Surgery Study scores.
• In contrast, physicians perceive that patients with diabetes
mellitus have a higher pretest likelihood of obstructive
coronary artery disease, an assessment supported by an
increased likelihood of a positive noninvasive test.
What Are the Clinical Implications?
• The presence of diabetes mellitus inﬂuences the diagnostic
pathway and results of noninvasive test among low-risk
patients with symptoms suggestive of coronary artery
disease.
• For patients with diabetes mellitus and stable chest pain
symptoms, additional strategies to assess for coronary
artery disease, including optimal test selection and risk
stratiﬁcation, need to be evaluated.
DOI: 10.1161/JAHA.117.007019 Journal of the American Heart Association 2
Impact of Diabetes Mellitus on the Evaluation of CAD Sharma et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
preferring stress nuclear over stress echocardiography dif-
fered between diabetic and nondiabetic patients who received
an imaging stress test.
To assess whether the likelihood of having a positive NIT
differed between patients with and without diabetes mellitus,
a logistic regression model was ﬁt. Adjusted analyses
controlled for randomized testing modality, age, and sex.
To determine the factors most predictive of a positive NIT in
patients with or without diabetes mellitus separately, multi-
variable logistic regression models were ﬁt using step-wise
variable selection with liberal entry and exit criteria (entry,
P<0.1; exit, P>0.2) to select the best subset of predictors from
among a comprehensive set of clinically guided candidate
predictors. The following candidate predictors were considered
for patients with or without diabetes mellitus: age; race; body
mass index; hypertension; sex; metabolic syndrome; dyslipi-
demia; history of carotid, peripheral vascular, or cerebrovas-
cular disease; history of heart failure; smoking (ever, never);
family history of premature CAD; depression; physical activity;
CAD equivalent; Framingham Risk Score (2008); ASCVD risk
prediction; Diamond-Forrester; Combined Diamond-Forrester
and CASS; Diamond-Forrester (2011); presenting symptom;
and chest pain characterization. In each case, age, sex, and
chest pain characterization were forced into the ﬁnal selected
model. Calibration of the ﬁnal models selected was assessed
using the Hosmer–Lemeshow goodness-of-ﬁt test, and dis-
crimination was assessed using the area under a receiver
operating characteristic curve.
All statistical calculations were conducted using SAS
(version 9.4; SAS Institute Inc, Cary, NC).
Results
Baseline Demographics and Primary Presenting
Symptoms
Patient distribution and study design are shown in Figure S1.
Among all enrolled patients (n=10 002), there were no
clinically signiﬁcant differences between patients with dia-
betes mellitus (n=2144) and those without diabetes mellitus
(n=7858) with regard to age (median 61 versus 60 years) or
sex (female 54% versus 52%). However, patients with diabetes
mellitus were more likely to have hypertension (80% versus
61%), dyslipidemia (77% versus 65%), depression (24% versus
20%), and a sedentary lifestyle (57% versus 47%; Table 1).
Patients with diabetes mellitus had a higher body mass index
(33 versus 29 kg/m2) and were more likely to have metabolic
syndrome (85% versus 25%; Table 1). Patients with diabetes
mellitus, compared with those without, were more likely to be
on aspirin, statin, beta-blocker, angiotensin-converting
enzyme inhibitor/angiotensin receptor blocker, or diuretics
(Table 1). At baseline, 74% of patients with diabetes mellitus
were on oral hypoglycemics, and 23% were on insulin, with the
remainder treated with diet alone.
Chest pain was the most common presenting symptom
among patients with and without diabetes mellitus (Table 1).
There was no difference in the characteristics of the chest
pain (ie, “aching/dull,” “burning/pins and needles,” or
“crushing/pressure/squeezing/tightness”) between patients
with and without diabetes mellitus. Patients with diabetes
mellitus were only slightly more likely to present with primary
nonchest pain symptoms compared with those without
diabetes mellitus (29% versus 27%), and dyspnea was more
frequent (18% versus 14%). Site physicians were more likely to
rate the chest pain among patients with diabetes mellitus as
being typical (14% versus 11%).
Risk Scores and Coronary Disease Likelihood
The predicted risks of cardiovascular events were higher for
patients with diabetes mellitus compared with those without
diabetes mellitus for the Framingham10 and ASCVD11 risk
scores (Table 2). The median pretest likelihood of obstructive
CAD was similar for patients with diabetes mellitus as
measured by the combined Diamond-Forrester and CASS12
(Table 2). Site physicians estimated that patients with
diabetes mellitus were less likely to have “very low” and
“low” pretest likelihood of obstructive CAD; conversely,
physicians estimated that patients with diabetes mellitus
were more likely to have “intermediate,” “high,” and “very
high” pretest likelihood of obstructive CAD.
Test Preferences
Before randomization, providers were asked their functional
test preference for each patient. Compared with patients
without diabetes mellitus, for those with diabetes mellitus,
exercise ECG (7% versus 11%; P<0.001) and stress echocar-
diography (19% versus 23%; P<0.001) were less frequently
speciﬁed whereas stress nuclear was more likely (74% versus
66%; P<0.001; Figure 1). Even after multivariable adjustment,
patients with diabetes mellitus were more likely to have an
imaging versus nonimaging test preferred (93% versus 89%;
adjusted odds ratio, 1.90; P<0.001; Table 3). Among those for
whom an imaging test was preferred, stress nuclear was
speciﬁed over stress echocardiography in both patients with
and without diabetes mellitus, although the preference was
stronger in those with diabetes mellitus (79% versus 74%;
adjusted odds ratio, 1.50; P<0.001; Table 3).
Test Results
Among the 8966 patients who received their initial NIT and
had interpretable results (1908 [21%] with diabetes mellitus
DOI: 10.1161/JAHA.117.007019 Journal of the American Heart Association 3
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Table 1. Patient Characteristics
Characteristic Diabetes Mellitus (N=2144) No Diabetes Mellitus (N=7858)
Demographics
Age, y
Median (25th, 75th) 60.6 (55.0, 66.3) 59.8 (54.3, 65.8)
Female sex, n/N (%) 1151/2144 (53.7) 4119/7858 (52.4)
Race, n/N (%)
Multiracial 19/2113 (0.9) 76/7802 (1.0)
White 1629/2113 (77.1) 6741/7802 (86.4)
Black 354/2113 (16.8) 742/7802 (9.5)
Asian 75/2113 (3.5) 178/7802 (2.3)
Indian 30/2113 (1.4) 41/7802 (0.5)
Hawaiian 6/2113 (0.3) 24/7802 (0.3)
Ethnicity, n/N (%)
Hispanic or Latino 256/2132 (12.0) 511/7812 (6.5)
Not Hispanic or Latino 1876/2132 (88.0) 7301/7812 (93.5)
Cardiac risk factors
BMI (kg/m2)
N 2117 7790
Median (25th, 75th) 32.8 (29.0, 37.4) 28.9 (25.8, 32.9)
Hypertension, n/N (%) 1712/2144 (79.9) 4789/7858 (60.9)
Dyslipidemia, n/N (%) 1656/2144 (77.2) 5111/7858 (65.0)
Smoker (ever/never), n/N (%) 1056/2144 (49.3) 4048/7856 (51.5)
Family history of premature CAD, n/N (%) 655/2140 (30.6) 2547/7830 (32.5)
Depression, n/N (%) 516/2142 (24.1) 1542/7858 (19.6)
Sedentary lifestyle, n/N (%) 1216/2142 (56.8) 3650/7840 (46.6)
Peripheral arterial disease or cerebrovascular disease, n/N (%) 165/2144 (7.7) 387/7857 (4.9)
Metabolic syndrome, n/N (%) 1822/2144 (85.0) 1950/7858 (24.8)
CAD risk equivalent, n/N (%) 2144/2144 (100.0) 387/7858 (4.9)
All primary presenting symptoms, n/N (%)
Arm or shoulder pain 55/2144 (2.6) 202/7852 (2.6)
Back pain 14/2144 (0.7) 70/7852 (0.9)
Chest pain* 1518/2144 (70.8) 5754/7852 (73.3)
Aching/dull 368/1518 (24.2) 1471/5754 (25.6)
Burning/pins and needles 138/1518 (9.1) 532/5754 (9.2)
Crushing/pressure/squeezing/tightness 746/1518 (49.1) 2854/5754 (49.6)
Other 461/1518 (30.4) 1738/5754 (30.2)
Fatigue or weakness 58/2144 (2.7) 219/7852 (2.8)
Neck or jaw pain 14/2144 (0.7) 95/7852 (1.2)
Palpitations 50/2144 (2.3) 186/7852 (2.4)
Dyspnea 375/2144 (17.5) 1115/7852 (14.2)
Other† 60/2144 (2.8) 211/7852 (2.7)
Continued
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and 7058 [79%] without diabetes mellitus), 15% of patients
with diabetes mellitus had positive NIT results compared
with 11% without diabetes mellitus (unadjusted odds ratio,
1.38; P<0.001; adjusted odds ratio, 1.23: P=0.010; Table 4).
Test positivity by testing modality is described in Figure 2.
The distribution of abnormal test results are described in
Table S1. Among those patients who underwent computed
tomography angiography, 15% of patients with diabetes
mellitus had positive test results compared with 11% of
those without diabetes mellitus. Among those who under-
went stress testing, 15% of patients with diabetes mellitus
had positive test results compared with 11% of those without
diabetes mellitus. NIT type did not modify the relationship
between diabetic status and test positivity (age- and sex-
adjusted interaction, P=0.93). Among patients with and
without diabetes mellitus, the risk of adverse outcomes is
greater among patients with a positive NIT result compared
with those with a negative NIT result (Table S2). The
presence of diabetes mellitus did not modify the relationship
between NIT result and death/myocardial infarction/unsta-
ble angina hospitalization (adjusted interaction P=0.179) or
cardiovascular death/myocardial infarction (adjusted inter-
action P=0.889).
Predictors of a Positive NIT
The clinical and demographic factors that were most predictive
of a positive stress test were determined separately for patients
with and without diabetes mellitus (Table 5). Age, sex, and
chest pain characteristicswere forced into bothmodels. Among
patients with diabetesmellitus, nonwhite race and Framingham
Risk Score provided additional predictive information, whereas
among those without diabetes mellitus, body mass index and
sedentary lifestyle provided additional prognostic information.
The ﬁnal areas under the curve of the models were modest at
0.64 for both patients with and without diabetes mellitus.
Discussion
Cardiovascular disease is the leading cause of death among
patients with diabetesmellitus; however, the impact of diabetes
mellitus on the clinical presentation, diagnostic evaluation, and
Table 1. Continued
Characteristic Diabetes Mellitus (N=2144) No Diabetes Mellitus (N=7858)
Physician characterization of chest pain, n/N (%)
Chest pain typicality
Typical 296/2144 (13.8) 870/7858 (11.1)
Atypical 1653/2144 (77.1) 6119/7858 (77.9)
Noncardiac 195/2144 (9.1) 869/7858 (11.1)
Medication use, n/N (%)
Aspirin 1098/2118 (51.8) 3181/7450 (42.7)
Statin 1291/2118 (61.0) 3097/7450 (41.6)
Beta-blocker 619/2118 (29.2) 1780/7450 (23.9)
ACEi or ARB 1444/2118 (68.2) 2750/7450 (36.9)
Diuretics 779/2118 (36.8) 1875/7450 (25.2)
Oral hypoglycemic‡ 1595/2144 (74.4) 0/7858 (0.0)
Insulin‡ 483/2144 (22.5) 0/7858 (0.0)
ECG findings, n/N (%)
ECG Q waves 126/2125 (5.9) 328/7784 (4.2)
ECG findings that could interfere with exercise stress test interpretation 147/2126 (6.9) 439/7784 (5.6)
LBBB 27/147 (18.4) 114/439 (26.0)
ST depression 31/147 (21.1) 94/439 (21.4)
LVH with repolarization 25/147 (17.0) 54/439 (12.3)
ACEi indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CAD, coronary artery disease; LBBB, left bundle branch block; LVH, left
ventricular hypertrophy.
*“Chest pain—substernal or left anterior” or “Chest pain other” are selected as primary symptoms. Multiple characterizations are possible.
†
Includes “Diaphoresis/sweating,” “Dizziness/lightheaded,” “Epigastric/abdominal pain,” “Nausea/vomiting,” “Syncope,” and Other.
‡
Data available only for patients with diabetes mellitus.
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NIT results among stable outpatients presenting with symp-
toms suggestive of CAD has not been well described. In our
analysis of the PROMISE trial, we identiﬁed the following major
ﬁndings: (1) There were signiﬁcant differences between
patients with and without diabetes mellitus in comorbidities
and cardiovascular risk, but clinical presentationwas similar; (2)
patients with and without diabetes mellitus had similar pretest
likelihood of obstructive CAD, but physicians perceived patients
with diabetes mellitus to have increased likelihood for obstruc-
tive CAD; (3) patients with diabetes mellitus were more likely to
be referred for stress imaging tests compared with those
without diabetes mellitus; (4) while patients with diabetes
mellitus were more likely to have a positive NIT result, the
absolute increase in risk was modest; and (5) predictors of a
positive NIT result differ between patients with and without
diabetes mellitus, but the ability to discriminate for a positive
NIT result was moderate in both groups.
Our study demonstrated that among stable patients with
symptoms suggestive of CAD, patients with diabetes mellitus
have a larger burden of cardiovascular risk factors such as
obesity, hypertension, and hypercholesterolemia. These
results align with other cohort studies of patients with
diabetes mellitus and suspected CAD undergoing stress
testing.15,16 Our study also identiﬁed that patients with
diabetes mellitus had a higher likelihood of emerging risk
factors, such as depression, a ﬁnding reported in other
nonchest pain cohorts.17 The increased burden of cardiovas-
cular risk factors is reﬂected in the higher cardiovascular
event risk scores in patients with diabetes mellitus compared
with those without diabetes mellitus (Table 2).
Our study is one of the largest assessments of the impact
of diabetes mellitus on the presentation of low- to interme-
diate-risk patients for symptoms suggestive of CAD. Most
studies evaluating the presentation of CAD in patients with
Table 2. Risk Scores and Assessment of Coronary Artery Disease Likelihood
Characteristic Diabetes Mellitus (N=2144) No Diabetes Mellitus (N=7858)
10-y CVD risk
Framingham risk score (2008)
N 2142 7846
Median (25th, 75th) 28.5 (18.8, 42.8) 14.7 (9.4, 24.4)
Low risk (<10%), n/N (%) 82/2142 (3.8) 2174/7846 (27.7)
Intermediate risk (10–20%), n/N (%) 534/2142 (24.9) 3010/7846 (38.4)
High risk (>20%), n/N (%) 1526/2142 (71.2) 2662/7846 (33.9)
ASCVD (2013)
N 2111 7790
Median (25th, 75th) 19.8 (11.7, 32.4) 9.7 (5.5, 16.6)
Low risk (<7.5%), n/N (%) 230/2111 (10.9) 2974/7790 (38.2)
Elevated risk (>7.5%), n/N (%) 1881/2111 (89.1) 4816/7790 (61.8)
Pretest likelihood of obstructive CAD
Combined Diamond-Forrester and CASS (2012)
N 2144 7858
Median (25th, 75th) 51.0 (31.0, 72.0) 51.0 (31.0, 72.0)
Low risk (<10%), n/N (%) 39/2144 (1.8) 211/7858 (2.7)
Intermediate risk (10–90%), n/N (%) 1978/2144 (92.3) 7279/7858 (92.6)
High risk (>90%), n/N (%) 127/2144 (5.9) 368/7858 (4.7)
Physician’s estimation of likelihood of significant CAD, n/N (%)*
Very low (<10%) 95/2141 (4.4) 540/7845 (6.9)
Low (10–30%) 510/2141 (23.8) 2610/7845 (33.3)
Intermediate (31–70%) 1368/2141 (63.9) 4382/7845 (55.9)
High (71–90%) 155/2141 (7.2) 293/7845 (3.7)
Very high (>90%) 13/2141 (0.6) 20/7845 (0.3)
ASCVD indicates Atherosclerotic Cardiovascular Disease; CAD, coronary artery disease; CASS, Coronary Artery Surgery Score; CVD, cardiovascular disease.
*Provider’s assessment of the likelihood that subject has signiﬁcant epicardial coronary stenosis or left main stenosis. Signiﬁcant refers to ≥70% epicardial coronary stenosis or ≥50% left
main stenosis.
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diabetes mellitus have focused on those presenting with
acute coronary syndromes,4–7 with some studies indicating
that patients with diabetes mellitus present with atypical
symptoms, whereas others do not.6,18,19 In a study of 4028
patients in Sweden presenting with their ﬁrst myocardial
infarction, diabetes mellitus was not an independent predictor
of atypical symptoms, and there were no differences in the
characteristics of symptoms between patients with and
without diabetes mellitus.19 However, as highlighted by a
previous study on sex differences in clinical presentation,
symptoms in an acute setting may not necessarily be
extrapolated to the stable outpatient setting.14 One large
cohort study of 8662 ambulatory patients with suspected
angina (906 with diabetes mellitus) identiﬁed that patients
with diabetes mellitus had a 2-fold increase in atypical
symptoms of angina (deﬁned as fewer than 2 of the following:
constricting quality, central or left-side location, ≤15 minutes
duration, and provocation by exercise).20 Our analysis
identiﬁed that in stable outpatients with symptoms suggestive
of CAD, those with and without diabetes mellitus had very
similar clinical presentations. Although patients with diabetes
mellitus may have differences in clinical presentation that
arise from neuropathy or comorbidities, such as obesity, this
was not reﬂected in our study population of stable patients
with symptoms suggestive of CAD.
Our study is one of the ﬁrst to evaluate the impact of
diabetes mellitus on the evaluation and testing of stable
outpatients with symptoms suggestive of CAD. Overall, our
results highlight that diabetes mellitus signiﬁcantly inﬂuences
the diagnostic pathway for suspected CAD. ECG exercise
stress testing has been reported to have similar sensitivity
and speciﬁcity among patients with and without diabetes
mellitus.21–23 However, imaging stress tests have greater
sensitivity compared with an exercise ECG test,24,25 leading to
calls to preferentially select imaging stress tests in diabetic
patients,26 a decision which may also be inﬂuenced by
physicians’ greater estimated risk of CAD in patients with
diabetes mellitus (Table 3). Patients with diabetes mellitus
may have decreased ability to exercise, as reﬂected by higher
prevalences of peripheral arterial disease, neuropathy, and
obesity, which may have inﬂuenced physician stress testing
preference. Furthermore, physician perception of increased
pretest likelihood of obstructive CAD among patients with
diabetes mellitus may have inﬂuenced test selection. In
addition, the greater likelihood of abnormalities on the
baseline ECG (such as Q waves or left bundle branch block)
among patients with diabetes mellitus may have also
inﬂuenced physicians to choose alternative NIT modalities.
In our study, physicians were more likely to select stress
nuclear over stress echocardiogram. This preference was
stronger in patients with diabetes mellitus compared with
those without diabetes mellitus despite limited studies in this
patient population to guide testing choices. For both stress
echocardiography and nuclear stress imaging, limited data
suggest that the sensitivity and speciﬁcity for CAD detection
among patients with and without diabetes mellitus are
similar.24,26–28 To date, there has been no head-to-head
comparison in patients with diabetes mellitus assessing the
Figure 1. Distribution of functional test preselection. ECHO
indicates echocardiogram.
Table 3. Association Between Diabetes Mellitus and Prespeciﬁed Choice of Functional Test Category
Diabetes Mellitus
n/N (%)
No Diabetes Mellitus
n/N (%)
Unadjusted
OR (95% CI); P Value
Adjusted
OR (95% CI); P Value*
Selection of imaging noninvasive test
1996/2144 (93) 7020/7858 (89) 1.91 (1.51–2.41); <0.001 1.90 (1.50–2.41); <0.001
Selection of a nuclear stress test (vs stress echo) in those for whom an imaging test was selected
1583/1996 (79) 5197/7020 (74) 1.51 (1.29–1.77); <0.001 1.50 (1.28–1.75); <0.001
CI indicates conﬁdence interval; OR, odds ratio.
*Adjusted model controls for age, sex, and testing site (random).
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accuracy of stress nuclear versus stress echocardiography to
guide NIT selection.
To our knowledge, our study has documented, for the ﬁrst
time, that in stable outpatients with symptoms of CAD,
patients with diabetes mellitus, compared with patients
without diabetes mellitus, have a greater risk of a positive
NIT. Previous studies have demonstrated similar rates of test
positivity between patients with and without diabetes mellitus
for exercise stress ECG,21 stress nuclear,24 and conﬂicting
results for stress echocardiography.16,28 The differences in
our results may reﬂect differences in patient selection
(previous studies were primarily convenience samples),
patient demographics, and risk-factor proﬁles. Although the
formal pretest scores suggest that patients with and without
diabetes mellitus have similar risk of obstructive CAD,
physicians perceive patients with diabetes mellitus to be at
higher risk of obstructive CAD. This is supported by the
observed increased risk of a positive NIT result. Given that
diabetes mellitus is an established cardiovascular risk factor,
further studies on the impact of diabetes mellitus on the
assessment of CAD is required.
The risk factors that predicted a positive stress test among
patients with and without diabetes mellitus were partially
overlapping, with race, typicality of chest pain, demographics,
and lifestyle variables included for both patient groups.
Among patients with diabetes mellitus, body mass index and
sedentary lifestyle do not add any signiﬁcant predictive
information. Among patients without diabetes mellitus, these
2 risk factors are signiﬁcant. Other demographic and presen-
tation characteristics, such as race and typicality of chest
pain, have differential predictive value among patients with
and without diabetes mellitus. These results suggest that
different factors may be present in the underlying pathogen-
esis of CAD among patients with and without diabetes
mellitus. However, the ability to discriminate for a positive
test was modest in both patients with and without diabetes
mellitus as reﬂected by the c-statistic. These results suggest
that other markers beyond baseline clinical and demographic
variables should be evaluated to improve discrimination for a
positive NIT among patients with and without diabetes
mellitus.
Strength and Limitations
The PROMISE trial enrolled the largest contemporary cohort
of low- to moderate-risk patients presenting with stable
symptoms of CAD studied to date. The pragmatic nature of
the trial inclusion criteria and its community setting provided
a unique opportunity to evaluate real-world differences
between patients with and without diabetes mellitus. Our
study is a post-hoc study and is subject to the inherent
limitations, although analysis by diabetic status was prespec-
iﬁed. However, it is possible that some sites may have
preferentially included or excluded diabetic patients, or those
with more atypical symptoms, thereby introducing some
selection bias. The presence of diabetes mellitus was
established by: (1) site investigator-reported history of
diabetes mellitus; and (2) the use of antidiabetic drugs. There
was no formal testing to conﬁrm the presence of diabetes
mellitus. Data on the type, duration, and degree of control of
diabetes mellitus were not available. Our use of imputation of
missing data for cholesterol and high-density lipoprotein has
the potential limitations of distorting the distribution of the
variable with missingness as well as its association with other
variables, but allowed calculation of Framingham and ASCVD
risk scores. The multivariable models evaluating the associ-
ation of presentation characteristics with NIT positivity were
Table 4. Association Between Diabetes Mellitus and Positive Initial Noninvasive Test Results
Diabetes Mellitus
n/N (%)
No Diabetes Mellitus
n/N (%)
Unadjusted
OR (95% CI); P Value
Adjusted
OR (95% CI); P Value*
289/1908 (15) 809/7058 (11) 1.38 (1.19–1.59); <0.001 1.38 (1.19–1.60); <0.001
CI indicates conﬁdence interval; OR, odds ratio.
*Adjusted model controls for age, sex, and noninvasive testing modality.
Figure 2. Test positivity by testing modality. CTA indicates
computed tomographic angiography; Echo, echocardiogram.
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exploratory, but have been used in a previous analysis of the
PROMISE trial.14
Conclusions
Diabetes mellitus signiﬁcantly affects clinical presentation,
risk-factor proﬁle, stress test selection, NIT results, and
predictors of a positive NIT among low-risk patients with
symptoms suggestive of coronary artery disease. However,
among patients with diabetes mellitus, typical chest pain is
the most common presenting complaint, and clinical presen-
tation is similar compared with patients without diabetes
mellitus. Patients with diabetes mellitus are more likely to be
referred for stress imaging tests than nonimaging test and,
speciﬁcally, nuclear tests. Furthermore, physicians estimate
that patients with diabetes mellitus have a higher risk of
obstructive CAD, and this assessment is supported by the
increased risk of a positive NIT observed in our study. Given
that diabetes mellitus is an established cardiovascular risk
factor, additional strategies to assess for coronary artery
disease, including optimal test selection and risk stratiﬁca-
tion, need to be evaluated for patients with diabetes mellitus
and stable chest pain symptoms.
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SUPPLEMENTAL MATERIAL 
 
 
 
Table S1. Severity of abnormal test results among patients with and without diabetes who have a 
positive non-invasive test. 
 Diabetes  
N= 1908 
Without diabetes 
N=7058 
CTA positive (%, of Total N undergoing 
CTA)# 
N= 139 (14.85%, n=936) N=395 (11.08%, n=3564) 
Number of vessels with stenosis ≥70% or left main ≥ 50% 
    Single vessel 94 (67.63%) 296 (74.94%) 
    Double vessel 27 (19.42%) 72 (18.23%) 
    Triple vessel 15 (12.95%) 26 (6.83%) 
ECG positive 
N=7 (9.21%, n=76) N= 47 (13.28%, n=354) 
Nuclear scan positive^  
N=126 (17.72%, n=711) N=309 (13.12%, n=2355) 
Number of coronary territories with inducible ischemia   
   1 98 (77.78%) 251 (81.23%) 
   2 24 (19.05%) 51 (16.50%) 
   3 3 (2.38%) 6 (1.94%) 
Echocardiogram positive 
N=17 (9.19%, n= 185) N=58 (7.39%, n=785) 
Number of coronary territories with inducible ischemia   
   1 12 (70.59%) 31 (53.45%) 
   2 3 (17.65%)  20 (34.48%) 
   3 2 (11.76%) 7 (12.07%) 
 
CTA indicates computed tomographic angiography; ECG, electrocardiogram. 
#3 patients with diabetes have disease in 4 vessels and 1 patient without diabetes has disease in 4 
vessels; ^ 1 patient with diabetes positive due to treadmill result and 1 patient without diabetes 
positive due to treadmill result; *Degree of ST depression not captured in case report form; †Test 
positivity included 1 patient in each group with an early positive ECG (< 3 min) but normal scan.  
  
 
 
Table S2. Unadjusted clinical event rates by noninvasive test positivity and diabetes history. 
 
Unadjusted Clinical Event Rate 
(No. of Events/Sample Size) 
Clinical Endpoint/Subgroup Positive NIT Negative NIT 
Death/MI/UAH    
Patients with diabetes 26/289 (9.00%) 49/1619 (3.03%) 
Patients without diabetes 70/809 (8.65%) 120/6249 (1.92%) 
Cardiovascular Death/MI    
Patients with diabetes  10/289 (3.46%) 25/1619 (1.54%) 
Patients without diabetes  23/809 (2.84%) 72/6249 (1.15%) 
 
MI indicates myocardial infarction; NIT, noninvasive test; UAH, unstable angina hospitalization. 
 
 
 
Figure S1. Patient distribution.  
 
Of the 10,003 enrolled patients, diabetic status was unknown in one. 
 
  
